Latest stories on TAK
Takeda’s Real-World Maribavir Study in Argentina: What Investors Should Watch
TipRanks53 · neutralproduct/pr
Takeda Links Executive Pay to R&D Progress and TSR as FY2025 Results Reset Growth Path
TipRanks58 · neutralgeneral
Takeda Details IFRS-Based Financial Notes and Group Restructuring in May 2026 Filing
TipRanks50 · neutralgeneral
Takeda Earnings Call: Pipeline Strength Amid Profit Squeeze
TipRanks58 · neutralearnings
Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict
Yahoo Top22 · bearishgeneral
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
Reuters33 · bearishgeneral
Takeda's Rich Pipeline Optionality Is Worth A 'Buy'
Seeking Alpha61 · neutralanalyst
Takeda's Next Wave of Drugs Has Investors Watching Closely
Yahoo Top58 · neutralproduct/pr
TAK Earnings: Stock Edges Up 0.6%—But Does History Signal a Bigger Move Ahead?
MarketChameleon53 · neutralearnings